Head to head
CagriSema against Semaglutide
The combination against one of its own halves. Both arms ran inside the same phase 3 trial, which is rarer than it sounds, so the question of what adding an amylin analogue buys on top of semaglutide has an answer from one randomised population rather than from two trials stitched together.
Column A
CagriSemaCagriSema (cagrilintide + semaglutide)
A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
Mean body weight fell 20.4 percent on cagrilintide plus semaglutide against 3.0 percent on placebo, a difference of 17.3 percentage points (95% CI 18.1 to 16.6, p < 0.001). Gastrointestinal adverse events affected 79.6 percent of the combination group against 39.9 percent on placebo and were mostly transient and mild to moderate. The published abstract reports the placebo comparison; it does not give a figure for the semaglutide-alone arm.
What the trial was
Phase 3a, 68 weeks, double-blind, placebo-controlled and active-controlled. 3,417 adults without diabetes with a BMI of 30 or more, or 27 or more with at least one obesity-related complication, randomised 21:3:3:7 to cagrilintide 2.4 mg plus semaglutide 2.4 mg (2,108), semaglutide 2.4 mg alone (302), cagrilintide 2.4 mg alone (302) or placebo (705), all with lifestyle intervention. The coprimary endpoints were relative change in body weight and the proportion losing 5 percent or more at week 68, both against placebo.
What the authors concluded
The authors state that cagrilintide and semaglutide given together provided significant and clinically relevant body weight reductions compared with placebo.
Where this result is weak
The semaglutide-alone arm existed but this trial was designed and powered against placebo, not against semaglutide, and it allocated seven times as many people to the combination as to either single agent. A 302 person comparator arm inside a 3,417 person trial supports description rather than a formal superiority claim. It ran 68 weeks, measured weight rather than any hard clinical outcome, and was funded by the manufacturer of both components.
REDEFINE 1 (NCT05567796), New England Journal of Medicine, 2025
Side by side, on the facts we can check
| Attribute | CagriSema | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026 | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~7 days (weekly dosing) | ~7 days |
| Molecular weight | Mixture; cagrilintide 4,409 Da plus semaglutide 4,113.6 Da | 4,113.6 Da |
| Mechanism | Simultaneously agonizes amylin receptors (satiety) and the GLP-1 receptor (appetite, insulin, gastric emptying) for additive weight loss. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 3 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between CagriSema and Semaglutide?
CagriSema: A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, CagriSema or Semaglutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the CagriSema profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CagriSema and Semaglutide FDA-approved?
CagriSema: Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover CagriSema or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.